Testosteron Cypionate 200mg/ml 10x1ml Ampullen by Pharma Group

Usage

1. Confirm your SARM suppression level at baseline using serum LH, FSH, and total testosterone before introducing Testosterone Cypionate as your base.
2. Select your weekly dose (100–200mg) based on the suppression profile of your chosen SARM(s) — more suppressive compounds such as RAD-140 require the full 200mg/1ml ampoule.
3. Score and snap the glass ampoule cleanly at the neck ring; draw the full 1ml content (or the appropriate partial volume) using a 21-gauge drawing needle into a sterile syringe.
4. Swap to a 23–25 gauge, 1-inch injection needle; administer intramuscularly into the glute, vastus lateralis, or deltoid, rotating sites each week across the 10-ampoule pack.
5. Schedule injections on a fixed weekly day — consistency in injection timing supports predictable serum androgen levels that keep the testosterone variable in your SARM stack stable, confirmed by mid-cycle bloodwork at week four.
6. At SARM cycle end, allow the cypionate depot to clear (approximately 14 days after the last injection) before initiating SERM-based PCT; do not begin PCT while Testosterone Cypionate is still actively suppressing the HPG axis.

Warnings

Frequently asked questions

Can Testosterone Cypionate from Pharma Group be used as a base compound alongside SARMs?

Yes — Testosterone Cypionate is specifically recommended as a suppression-management base during SARM cycles. SARMs such as LGD-4033 and RAD-140 suppress endogenous testosterone production; co-administering exogenous testosterone at 100–200mg per week prevents symptomatic hypogonadism without turning the testosterone itself into the primary anabolic agent of the stack.

Which SARMs are most commonly combined with a Testosterone Cypionate base?

Ligandrol (LGD-4033), RAD-140, and Ostarine (MK-2866) are the most frequently reported SARMs run alongside a testosterone base. LGD-4033 and RAD-140 produce meaningful HPG axis suppression within 2–4 weeks, making the cypionate depot particularly valuable; Ostarine at low doses causes milder suppression but still benefits from testosterone support in cycles longer than eight weeks.

What should I monitor when stacking SARMs with Testosterone Cypionate?

Monitor serum LH, FSH, and total testosterone at baseline and at week four to assess suppression depth. Track haematocrit, estradiol, and lipid panels throughout — SARMs can negatively affect HDL cholesterol independently of testosterone, and combined use compounds this risk. Liver enzyme panels (ALT, AST) are advisable if any orally administered SARM is included in the stack.

Why does the 200mg/ml concentration suit SARM-stack testosterone dosing better than stronger formulations?

At 200mg/ml, a 100mg base dose equals exactly 0.5ml and a 200mg dose equals 1ml — clean, measurable volumes that eliminate dosing error at the conservative end of the range. Higher-concentration products at 250mg/ml or 300mg/ml compress these doses into sub-0.5ml volumes that introduce measurement imprecision, especially relevant for SARM users targeting consistency over anabolic maximisation.

How does the 10x1ml single-dose ampoule format benefit a multi-week SARM cycle?

Each ampoule is factory-sealed and intended for single use, which means every injection across an 8–12 week SARM cycle is drawn from a previously unopened sterile unit. This eliminates the microbial contamination risk that accumulates with multi-dose vials punctured weekly for three months. The 10-ampoule pack also maps cleanly to a ten-week base-dose protocol at one ampoule per week. (2) angle_used

Manufacturer

Pharma Group's quality approach to its Testosterone Cypionate product centres on a single non-negotiable starting point: active pharmaceutical ingredient (API) origin and identity. Every batch of Testosterone Cypionate API entering the Pharma Group production chain is sourced from documented suppliers whose raw material certificates include synthesis origin, purity assay, and residual solvent profiles — documentation reviewed and cross-validated in-house before the API advances to the weighing stage. Identity confirmation is performed by infrared spectroscopy against pharmacopoeial reference standards, and potency is independently re-assayed by reversed-phase HPLC rather than accepted on supplier documentation alone; the HPLC result printed on each batch record is the figure that governs release, not the certificate of analysis provided externally. This API-first discipline is particularly relevant for a 200mg/ml injectable product intended for long-cycle SARM base dosing, where batch-to-batch concentration variance would directly distort the testosterone variable users rely on for consistent stack outcomes. Final release requires LAL bacterial endotoxin clearance and sterile fill-and-seal processing within a GMP-classified cleanroom — the documented convergence of clean raw materials, verified concentration, and controlled aseptic manufacture.